Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Date publication

mars 2018

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29511561

Résumé

In clinical practice, treatment sequences of biologicals are applied for active fistulising Crohn's disease, however underlying health economic analyses are lacking.

Mots clés

Cost-effectiveness, adalimumab, biosimilar, biosimilar-infliximab, fistulising Crohn’s disease, infliximab, vedolizumab

Référence

United European Gastroenterol J. 2018 Mar;6(2):310-321